Researched applications In the published preclinical and clinical literature the effects of AOD-9604 are documented in the following areas: Obesity , Phase 2b failure (2007), but a complementary mechanism in combination protocols Lipolysis in animal models , robustly demonstrated (Heffernan 2001, Ng 2009) Inhibition of lipogenesis , demonstrated in hepatocytes and adipocytes Osteoarthritis and cartilage regeneration , emerging Phase 1/2 data (mLuna Pharmaceuticals 2018+) Tendinopathy , preclinical models Age-related sarcopenia (cachexia) , exploratory plans Lipodystrophy , preclinical data in animal models Hyperlipidemia , secondary endpoints in Phase 2 trials Science & studies 4.1 Key publications Heffernan M., Summers R.J., Thorburn A., et al
The dosage and frequency of therapy required depends on the clinical condition of the animal and the copper status, as assessed by blood and liver levels both before and after therapy
State Law prohibits the return of items purchased with a prescription
ebei, B., Nikoli, V., Sikiri, P., Seiwerth, S., oa, T., Patrlj, L., Grabarevi, ., Ruman, R., Petek, M., Konjevoda, P., Jadrijevi, S., Perovi, D., & laj, M